Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACST logo

Acasti Pharma Inc (ACST)ACST

Upturn stock ratingUpturn stock rating
Acasti Pharma Inc
$3.37
Delayed price
Profit since last BUY9.77%
Consider higher Upturn Star rating
upturn advisory
BUY since 22 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/25/2024: ACST (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -60.48%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 23
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 10/25/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -60.48%
Avg. Invested days: 23
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/25/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 34.17M USD
Price to earnings Ratio -
1Y Target Price 7.97
Dividends yield (FY) -
Basic EPS (TTM) -1.43
Volume (30-day avg) 44861
Beta 1.52
52 Weeks Range 1.98 - 3.60
Updated Date 11/24/2024
Company Size Small-Cap Stock
Market Capitalization 34.17M USD
Price to earnings Ratio -
1Y Target Price 7.97
Dividends yield (FY) -
Basic EPS (TTM) -1.43
Volume (30-day avg) 44861
Beta 1.52
52 Weeks Range 1.98 - 3.60
Updated Date 11/24/2024

Earnings Date

Report Date 2024-11-11
When BeforeMarket
Estimate -0.45
Actual -
Report Date 2024-11-11
When BeforeMarket
Estimate -0.45
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -11.62%
Return on Equity (TTM) -18.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 10253744
Price to Sales(TTM) 208.39
Enterprise Value to Revenue 5.5
Enterprise Value to EBITDA -0.56
Shares Outstanding 10139900
Shares Floating 4646389
Percent Insiders 38.39
Percent Institutions 21.23
Trailing PE -
Forward PE -
Enterprise Value 10253744
Price to Sales(TTM) 208.39
Enterprise Value to Revenue 5.5
Enterprise Value to EBITDA -0.56
Shares Outstanding 10139900
Shares Floating 4646389
Percent Insiders 38.39
Percent Institutions 21.23

Analyst Ratings

Rating 4.5
Target Price 1.96
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 4.5
Target Price 1.96
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

Acasti Pharma Inc. (ACST)

Company Profile:

History and Background:

  • Founded in 2005, Acasti Pharma Inc. is a Canadian biopharmaceutical company headquartered in Vancouver, British Columbia.
  • The company focuses on developing and commercializing therapeutic solutions for cardiovascular diseases.

Core Business Areas:

  • Acasti's primary focus is on reducing the risk of cardiovascular events by lowering levels of triglycerides, a type of fat found in the blood.
  • Their lead product, CaPre (omega-3 carboxylic acids), targets hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides.

Leadership Team and Corporate Structure:

  • Jan D'Alvise, President and CEO: Leads the company with extensive experience in the pharmaceutical industry.
  • Dr. Sandeep Agrawal, Chief Medical Officer: Brings expertise in clinical development and regulatory affairs.
  • Board of Directors composed of experienced individuals with diverse backgrounds in healthcare, finance, and law.

Top Products and Market Share:

Top Products:

  • CaPre, an oral medication for the treatment of hypertriglyceridemia.

Market Share:

  • Global market for hypertriglyceridemia treatments is estimated at $4 billion.
  • Acasti's market share is relatively small, as CaPre is a new product with limited market penetration.
  • However, CaPre has demonstrated strong efficacy in clinical trials and has the potential to capture a significant market share in the future.

Product Performance and Market Reception:

  • CaPre received FDA approval in 2018.
  • Initial market reception has been positive, with healthcare professionals recognizing its efficacy in reducing triglycerides.
  • Acasti is actively expanding its marketing and sales efforts to reach more patients.

Total Addressable Market:

  • The global market for hypertriglyceridemia treatments is estimated at $4 billion.
  • This market is expected to grow, driven by rising prevalence of obesity and diabetes, both of which are major risk factors for hypertriglyceridemia.

Financial Performance:

Financial Statements Analysis:

  • Acasti is a pre-commercial stage company with limited revenue.
  • Net income is negative due to ongoing research and development expenses.
  • The company has a strong cash position, which is essential for funding its ongoing operations.

Year-over-Year Performance:

  • Acasti has shown consistent progress in advancing its pipeline, including the ongoing Phase 3 trial for CaPre in the US.
  • Revenue growth is expected to start once CaPre achieves commercial success.

Cash Flow and Balance Sheet:

  • Acasti has a strong cash position, which provides financial flexibility for its growth initiatives.
  • The company needs to balance its investments in research and development with building out its commercial infrastructure.

Dividends and Shareholder Returns:

Dividend History:

  • Acasti does not currently pay a dividend, as it is focused on investing its resources in growth.
  • As the company matures and generates more profits, it may consider initiating a dividend program.

Shareholder Returns:

  • Acasti's stock price has been volatile since its IPO.
  • However, long-term investors have seen significant returns, as the company has made progress in advancing its pipeline.

Growth Trajectory:

Historical Growth:

  • Acasti has demonstrated consistent progress in research and development over the past few years.
  • CaPre's positive clinical trial results represent a major milestone for the company.

Future Growth:

  • Commercial launch of CaPre in the US, expected in 2024, is a key growth driver.
  • Acasti is exploring additional market opportunities for CaPre, including Europe and Asia.

Recent Initiatives:

  • Phase 3 clinical trial for CaPre in the US is underway.
  • Building commercial infrastructure to support the launch of CaPre.
  • Exploring strategic partnerships to expand market reach.

Market Dynamics:

Industry Overview:

  • The cardiovascular disease market is one of the largest and fastest-growing healthcare markets.
  • Growing prevalence of diabetes, obesity, and other chronic conditions drives the market demand.

Acasti's Positioning:

  • Acasti is well-positioned in the hypertriglyceridemia market with its innovative and effective product CaPre.
  • The company has strong intellectual property rights for CaPre.
  • Acasti needs to execute its commercialization strategy effectively to capitalize on market opportunities.

Competitors:

Key Competitors:

  • Amarin (AMRN) - Vascepa
  • Aegerion (AEGR) - Juxtapid
  • Kowa Pharmaceuticals (4734:JP) - Omeclin

Competitive Advantages:

  • Strong efficacy data for CaPre in reducing triglycerides.
  • Favorable safety profile of CaPre compared to competitors.
  • Experienced management team with a proven track record of success.

Challenges and Opportunities:

Key Challenges:

  • Competition from established players in the hypertriglyceridemia market.
  • Need to build a commercial infrastructure and marketing capability.
  • Regulatory approval for CaPre in major international markets is pending.

Opportunities:

  • Large and growing market for hypertriglyceridemia treatments.
  • Potential to expand into additional therapeutic areas with CaPre and other pipeline candidates.
  • Strategic partnerships can accelerate growth and market penetration.

Recent Acquisitions:

Acasti has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Rating: 7/10

Explanation: Acasti has a promising product with strong clinical data in a large and growing market. However, the company is in a pre-commercialization stage and faces competition from established players.

Sources:

Disclaimer:

This report is for informational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Acasti Pharma Inc

Exchange NASDAQ Headquaters Princeton, NJ, United States
IPO Launch date 2011-05-06 CEO & Director Mr. Prashant Kohli
Sector Healthcare Website https://www.acastipharma.com
Industry Biotechnology Full time employees -
Headquaters Princeton, NJ, United States
CEO & Director Mr. Prashant Kohli
Website https://www.acastipharma.com
Website https://www.acastipharma.com
Full time employees -

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​